Floatz logo

Lacosamide

Alzheimer Disease 3

Xiangya Hospital of Central South UniversitySmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Alzheimer Disease 3 cohort.

Asset / SponsorPhaseRating
Aph-1105
Aphios
Phase 2CCC
2-Bromo-?-ergocryptine
Kyoto University
Phase 1/2CCC

Same molecule, other indications

Lacosamide is also rated in:

focal epilepsyDormant
A
Indicative ·
80 / 100
View asset →
epilepsyDormant
BBB
Indicative ·
74 / 100
View asset →
Partial Onset SeizuresDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →